A randomized study of two vindesine plus cisplatin‐containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non‐small cell lung cancer

R. Rosell, A. Abad‐Esteve, I. Moreno, A. Barnadas, J. Carles, C. Fernandez, N. Ribelles, M. Culubret

Research output: Contribution to journalArticleResearchpeer-review

30 Citations (Scopus)

Abstract

The current trial was carried out to assess the survival enhancement achieved, if any, by adding ifosfamide to vindesine and cisplatin (IVP) in contrast to mitomycin plus vindesine and cisplatin (MVP). Between June 1986 and September 1988, 110 patients were randomly allocated to receive either ifosfamide (3 g/m2 plus 3 g/m2 of mesna) or mitomycin 8 mg/m2, on days 1, 29, and 71 only. In both arms vindesine was given 3 mg/m2 weekly X 5 then every 2 weeks. In the MVP arm, 120 mg/m2 of cisplatin was administered on days 1 and 29 and then every 6 weeks, whereas in the IVP arm 100 mg/m2 of cisplatin was given on the same time schedule. One hundred three patients were evaluable for response and toxicity and 56% of patients had Mountain's Stage IV disease. The response rate was 26% (14/53 patients) in the MVP arm (95% confidence interval, 14%‐39%) and 20% (ten of 50 patients) in the IVP arm (95% confidence interval, 10%‐34%). Neither the response rate nor the median survival times were significantly different, although more nephrotoxicity was produced in the MVP arm, grade 1+ in 43% versus 26% in IVP arm (P = 0.04). Results obtained from this study fail to demonstrate that mitomycin or ifosfamide have a synergistic effect on the efficacy of the vindesine/cisplatin combination. Copyright © 1990 American Cancer Society
Original languageEnglish
Pages (from-to)1692-1699
JournalCancer
Volume65
Issue number8
DOIs
Publication statusPublished - 1 Jan 1990

Fingerprint Dive into the research topics of 'A randomized study of two vindesine plus cisplatin‐containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non‐small cell lung cancer'. Together they form a unique fingerprint.

Cite this